3EYG

Crystal structures of JAK1 and JAK2 inhibitor complexes

3EYG の概要

• エントリーDOI: 10.2210/pdb3eyg/pdb
• 関連するPDBエントリー: 3EYH
• 分子名称: Tyrosine-protein kinase, 3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile (3 entities in total)
• 機能のキーワード: jak kinase, atp-binding, kinase, nucleotide-binding, phosphoprotein, sh2 domain, transferase, tyrosine-protein kinase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 33801.58

構造登録者

Williams, N.K.,Bamert, R.S.,Patell, O.,Wang, C.,Walden, P.M.,Fantino, E. (登録日: 2008-10-20, 公開日: 2009-02-03, 最終更新日: 2024-10-30)

主引用文献

Williams, N.K.,Bamert, R.S.,Patel, O.,Wang, C.,Walden, P.M.,Wilks, A.F.,Fantino, E.,Rossjohn, J.,Lucet, I.S.
Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains.
J.Mol.Biol., 387:219-232, 2009

PubMed Abstract: The Janus kinases (JAKs) are a pivotal family of protein tyrosine kinases (PTKs) that play prominent roles in numerous cytokine signaling pathways, with aberrant JAK activity associated with a variety of hematopoietic malignancies, cardiovascular diseases and immune-related disorders. Whereas the structures of the JAK2 and JAK3 PTK domains have been determined, the structure of the JAK1 PTK domain is unknown. Here, we report the high-resolution crystal structures of the "active form" of the JAK1 PTK domain in complex with two JAK inhibitors, a tetracyclic pyridone 2-t-butyl-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinoline-7-one (CMP6) and (3R,4R)-3-[4-methyl-3-[N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropionitrile (CP-690,550), and compare them with the corresponding JAK2 PTK inhibitor complexes. Both inhibitors bound in a similar manner to JAK1, namely buried deep within a constricted ATP-binding site, thereby providing a basis for the potent inhibition of JAK1. As expected, the mode of inhibitor binding in JAK1 was very similar to that observed in JAK2, highlighting the challenges in developing JAK-specific inhibitors that target the ATP-binding site. Nevertheless, differences surrounding the JAK1 and JAK2 ATP-binding sites were apparent, thereby providing a platform for the rational design of JAK2- and JAK1-specific inhibitors.

PubMed: 19361440
DOI: 10.1016/j.jmb.2009.01.041

実験手法

X-RAY DIFFRACTION (1.9 Å)